We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Identifies Amino Acid Metabotypes Associated with Autism

By LabMedica International staff writers
Posted on 06 Mar 2019
Autism spectrum disorder (ASD) could benefit from new and improved diagnostic methods and the arrival of a newly commercialized blood test, along with other efforts headed toward a similar end goal, and could be nudging the field toward earlier detection and intervention.

ASD is a developmental disability that can cause various social, communication, and behavioral challenges, such as speech disturbances, repetitive behaviors, limited interests, anxiety, and difficulty adapting to new environments. More...
Although it can potentially be detected at 18 months or younger, current methods of diagnosis rely on behavioral assessments.

NeuroPointDX (Madison, WI, USA), a division of Stemina Biomarker Discovery, announced the commercial launch of its NPDX AA test to help with the earlier diagnosis of ASD. The blood plasma-based test, which identifies amino acid metabotypes (subtypes based on metabolism) associated with ASD, can be used to screen children as young as 18 months. The test is capable of identifying metabotypes in about 30% of children with ASD, based on data from the Children’s Autism Metabolome Project (CAMP), which is the largest clinical study to date focused on the metabolism of children with ASD. Each of those subtypes is identified with greater than 95% specificity. The NPDX AA test is intended for children who have a developmental delay and for younger siblings of children who have already been diagnosed, both of which indicate a higher risk for ASD.

The test, initially available on a limited basis, must be ordered by a physician and requires a fasting blood sample, which can be taken by a phlebotomy lab. The laboratory then ships the sample, following certain protocols, to NeuroPointDX’s laboratory. From there, a report is returned to the physician within two weeks to indicate whether or not the child is positive for any of the metabotypes. Children who receive a positive result are at an increased risk and should be prioritized for additional evaluation.

David Amaral, PhD, director of the University of California, Davis MIND Institute Autism Center of Excellence (Davis, CA, USA) and principal investigator in the CAMP study said, “If we had a more objective biological marker that could be used during the first year of life or even between one and two, we could get children into effective intervention much, much earlier.”

Related Links:
NeuroPointDX
University of California, Davis MIND Institute Autism Center of Excellence


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.